We then applied inverse probability weighting to balance the health and demographic characteristics between antihyperglycemics users who received SGLT2 inhibitors vs those who did not (the control group) and evaluated whether treatment with SGLT2 inhibitors was associated with reduced risk of MACE (defined as composite of death, myocardial infarction and stroke) and MAKE (defined as composite of death, eGFR decline > 50%, and end stage kidney disease (ESKD)). This evidence concerns the gene SLC5A2 and Stroke.